Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Update Il y a 4 ans
Reference: NCT02696642

Woman and Man

Extract

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment


Inclusion criteria

  • Neoplasms

Links